Schizophrenia linked to increased insulin resistance

A study published inBiomarker Studies of Metabolic and Metabolism-Related Disorders suggests that patients with schizophrenia have an increased risk of insulin resistance and metabolic syndrome. Psychiatry Advisor
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

Conclusions: An interdisciplinary approach is required between neurosciences and cardiology not only at the research level, but also in the clinical practice. Cardiac co-morbidity in subjects with schizophrenia may critically affect the survival rates of these patients. Moreover, the nature of the cardiac co-morbidity may guide the clinician in better understanding and differentiating functional psychoses from organic ones. The multifactorial approach can identify cardiovascular risk factors based on clinical, biological and neuroimaging markers. PMID: 32239085 [PubMed - in process]
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Authors: Zhang Y, Wang Q, Reynolds GP, Yue W, Deng W, Yan H, Tan L, Wang C, Yang G, Lu T, Wang L, Zhang F, Yang J, Li K, Lv L, Tan Q, Li Y, Yu H, Zhang H, Ma X, Yang F, Li L, Chen Q, Wei W, Zhao L, Wang H, Li X, Guo W, Hu X, Tian Y, Ren H, Ma X, Coid J, Zhang D, Li T, Chinese Antipsychotics Pharmacogenomics Consortium Abstract OBJECTIVE: To compare longitudinal metabolic effects of 7 antipsychotics, including body mass index (BMI), waist circumference (WC), blood pressure (BP), glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C); to investigate ...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Aripiprazole is an atypical antipsychotic that is usually well tolerated. It is FDA approved for treatment for schizophrenia and mania in Bipolar Disorder. Off label use includes augmentation protocols for depression and anxiety disorders as well as aggression in the pediatric population. Properties include 5-HT1A partial agonism and 5HT1-A antagonism along with D2 and D3 agonism. Abilify is often preferred due to reduced risk of metabolic syndrome, extrapyramidal symptoms and minimal sedative profile.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Poster Number: EI-51 Source Type: research
Loneliness is common in schizophrenia with prevalence estimates as high as 80% among people with schizophrenia. Recent studies among non-psychiatric samples have indicated deleterious effects of loneliness on physical health and mortality, including increased risk of hypertension, central obesity, metabolic syndrome, coronary heart disease, stroke, and other cardiovascular disorders. The all-cause mortality risk of loneliness is double that from obesity and equivalent to that from smoking ¾ of a pack of cigarettes per day.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Poster Number: NR - 23 Source Type: research
CONCLUSION: Early recognition and accurate diagnosis of BD, which enables adequate and timely treatment, can improve outcomes. PMID: 32125440 [PubMed - as supplied by publisher]
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research
Metabolic side effects such as weight gain and disturbed lipid metabolism are often observed in the treatment of atypical antipsychotic drugs (AAPDs), which contribute to an excessive prevalence of metabolic syndrome among schizophrenic patients. Great individual differences are observed but the underlying mechanisms are still uncertain. Research on pharmacogenomics indicates that gene polymorphisms involved in the pathways controlling food intake and lipid metabolism may play a significant role. In this review, relevant genes (HTR2C, DRD2, LEP, NPY, MC4R, BDNF, MC4R, CNR1, INSIG2, ADRA2A) and genetic polymorphisms related...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Individuals with severe mental illness (SMI), such as schizophrenia and bipolar affective disorder, have a higher risk of physical illness than those without SMI[1]. These physical illnesses exist within the general population, but the incidence and impact on morbidity and mortality in those with SMI is significantly ...
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Authors: Barton BB, Segger F, Fischer K, Obermeier M, Musil R Abstract Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often neglected side-effect in the treatment with first and second generation antipsychotics. AIWG can increase the risk of developing metabolic syndrome, diabetes and cardiovascular disease. Meta-analyses mostly concentrate on AIWG in schizophrenic and bipolar patients, even though antipsychotics are prescribed off-label across many other diagnostic groups (e.g. anxiety disorders, depression, autistic disorder).Areas covered: Pub Med and Web of Science were systemat...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
CONCLUSION: Clarity of diagnostic criteria for myocarditis remains a challenge. Observation bias may, in part, influence higher reported rates in Australia. Monitoring for myocarditis is warranted in the first 4 weeks, and treatment of comorbid metabolic syndrome and diabetes may reduce the risk of cardiomyopathy. The risks of myocarditis and cardiomyopathy are low and should not present a barrier to people with treatment refractory schizophrenia being offered a monitored trial of clozapine. PMID: 31957459 [PubMed - as supplied by publisher]
Source: The Australian and New Zealand Journal of Psychiatry - Category: Psychiatry Authors: Tags: Aust N Z J Psychiatry Source Type: research
ConclusionThese findings show that clozapine enhances the motivation to work for food, that this effect is stable over repeated testing, and is independent of hunger state of the animal. This effect may relate to a combined action of clozapine at the serotonin 5-HT2C and histaminergic H1 receptors.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
More News: Endocrinology | Insulin | Metabolic Syndrome | Psychiatry | Schizophrenia | Study